Blood-based gene expression profiling in castrate-resistant prostate cancer

BMC Medicine

Mitchell E. Gross¹ 

[1] Center for Applied Molecular Medicine, Keck School of Medicine, University of Southern California, 9033 Wilshire Boulevard, Suite 300, Beverly Hills 90211, CA, USA

关键词: Prognostic biomarker;    Gene expression profiling;    Castrate-resistant prostate cancer;   

Others  :  1225015
DOI  :  10.1186/s12916-015-0463-8

 received in 2015-08-27, accepted in 2015-08-27,  发布年份 2015

【 摘 要 】

Castrate-resistant prostate cancer (CRPC), the most life-threatening form of prostate cancer, has recently been the focus of many successful new treatments. Contemporary trials highlight the heterogeneous prognosis of CRPC as overall survival times vary greatly across different patient sub-groups. As presented in BMC Medicine, Wang et al. identify a blood-based prognostic signature in CRPC. Their approach is notable for discovery and validation of a four-gene model based on a whole-blood expression signature sampled from three distinct clinical cohorts. Further, the marker selection process incorporates an understanding of biological pathways expressed in myeloid or lymphoid cells which may provide some insight into host-tumor interactions as reflected in the peripheral blood. While the study includes a multivariate analysis accounting for many important clinical variables, larger datasets with more complete clinical information and sufficient follow-up are needed to confirm the independent significance of the four-gene expression model in a way which may better inform the care of CRPC patients.

Please see related article: http://www.biomedcentral.com/1741-7015/13/201.

【 授权许可】

   
2015 Gross.

【 参考文献 】

• [1]Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26:v69-v77.
• [2]Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P et al.. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013; 368:138-48.
• [3]Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al.. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371:424-33.
• [4]Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD et al.. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369:213-23.
• [5]Wang L, Gong Y, Chippada-Venkata U, Heck MM, Retz M, Nawroth R et al.. A robust blood gene expression-based prognostic model for castrate-resistant prostate cancer. BMC Med. 2015; 13:201. BioMed Central Full Text
• [6]Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G et al.. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. Lancet Oncol. 2012; 13:1114-24.
• [7]Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS et al.. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol. 2012; 13:1105-13.
• [8]Tudoran O, Virtic O, Balacescu L, Pop L, Dragla F, Eniu A et al.. Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One. 2014; 9:e102764.
• [9]Ciarloni L, Hosseinian S, Monnier-Benoit S, Imaizumi N, Dorta G, Ruegg C. Discovery of a 29-gene panel in peripheral blood mononuclear cells for the detection of colorectal cancer and adenomas using high throughput real-time PCR. PLoS One. 2015; 10:e0123904.
• [10]Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J et al.. Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res. 2013; 3:523-9.
• [11]Nonomura N, Takayama H, Nakayama M, Nakai Y, Kawashima A, Mukai M et al.. Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer. BJU Int. 2011; 107:1918-22.
• [12]Lorente D, Mateo J, Templeton AJ, Zafeiriou Z, Bianchini D, Ferraldeschi R et al.. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate cancer independent of baseline steroid use. Ann Oncol. 2015; 26:750-5.
• [13]Sonpavde G, Pond GR, Armstrong AJ, Clarke SJ, Vardy JL, Templeton AJ et al.. Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2014; 12:317-24.
• [14]Templeton AJ, Pezaro C, Omlin A, McNamara MG, Leibowitz-Amit R, Vera-Badillo FE et al.. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014; 120:3346-52.
• [15]van Soest RJ, Templeton AJ, Vera-Badillo FE, Mercier F, Sonpavde G, Amir E et al.. Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials. Ann Oncol. 2015; 26:743-9.
• [16]Strasner A, Karin M. Immune infiltration and prostate cancer. Front Oncol. 2015; 5:128.
• [17]Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al.. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363:411-22.